The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Open accessPublished version of a preprint
Abstract
A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world 1-3. Here, to better understand the initial step of infection at an atomic level, we determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor 4. Structural analysis identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses 1-3,5. The epitopes of two SARS-CoV antibodies that target the RBD are also analysed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This amino acid sequence extends from residue Thr333 to residue Gly526 [28].”
From Effects of Mangiferin on LPS-Induced Inflammation and SARS-CoV-2 Viral Adsorption in Human Lung Cells (2022) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, ACE2 (angiotensin-converting enzyme 2) had been identified as the receptor for SARS-CoV 4,5 and SARS-CoV-2.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [7]
In the citing paper
“When binding to hACE2, spike amino acid F486 interacts with hACE2 residues L79, M82 and Y83, which collectively comprise a hotspot for ACE2 differences between mammalian species13.”
From Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citation[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationPhaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationMartínez–González, M. B. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,292
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961
Cited by
Sorted by citations
Items 101–200 of 1,026
Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470
Mutations Strengthened SARS-CoV-2 Infectivity
Chen, J., Wang, R., Wang, M., & Wei, G. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.07.009 · Cited by 468
The hallmarks of COVID-19 disease
Tang, D., Comish, P. B., & Kang, R. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008536 · Cited by 467
Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106267 · Cited by 462
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 462
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“These severe cases that develop respiratory failure show a series of pathological findings such as hyaline membrane formation, inflammatory infiltration with multinucleated syncytial cells in their lung pathology and a burst of cytokine release leading to morbidity and mortality [6,12].”
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 456
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Zahradník, J., Marciano, S., Shemesh, M., Zoler, E., Harari, D., Chiaravalli, J., Meyer, B., Rudich, Y., Li, C., Marton, I., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00954-4 · Cited by 454
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Severe covid-19 pneumonia: pathogenesis and clinical management
Attaway, A. H., Scheraga, R. G., Bhimraj, A., Biehl, M., & Hatipoglu, U. S. (2021) · BMJ · doi:10.1136/bmj.n436 · Cited by 452
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor
Zhao, P., Praissman, J. L., Grant, O. C., Cai, Y., Xiao, T., Rosenbalm, K. E., Aoki, K., Kellman, B. P., Bridger, R., Barouch, D. H., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.004 · Cited by 450
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H. E., Batten, C. J., Mordant, F. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0995-0 · Cited by 437
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V. V., Hoppe, N., Boone, M., Billesbølle, C. B., Puchades, C., Azumaya, C. M., et al. (2020) · Science · doi:10.1126/science.abe3255 · Cited by 432
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D’Agnano, V., Komici, K., Mazzarella, G., Parrella, R., & Bianco, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01631-y · Cited by 430
Magleby, R., Westblade, L. F., Trzebucki, A. M., Simon, M. S., Rajan, M., Park, J. C., Goyal, P., Safford, M. M., & Satlin, M. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa851 · Cited by 429
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 429
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103154118 · Cited by 429
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Toelzer, C., Gupta, K., Yadav, S. K. N., Borucu, U., Davidson, A. D., Williamson, M. K., Shoemark, D. K., Garzoni, F., Staufer, O., Milligan, R., et al. (2020) · Science · doi:10.1126/science.abd3255 · Cited by 427
Digital Screen Time During the COVID-19 Pandemic: Risk for a Further Myopia Boom?
Wong, C. W., Tsai, A. S. H., Jonas, J. B., Ohno‐Matsui, K., Chen, J., Ang, M., & Ting, D. S. W. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.034 · Cited by 419
Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576622 · Cited by 417
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.019 · Cited by 410
Self-citationEmergence of SARS-CoV-2 through recombination and strong purifying selection
Li, X., Giorgi, E. E., Marichannegowda, M. H., Foley, B. T., Xiao, C., Kong, X., Chen, Y., Gnanakaran, S., Korber, B., & Gao, F. (2020) · Science Advances · doi:10.1126/sciadv.abb9153 · Cited by 407
Structural impact on SARS-CoV-2 spike protein by D614G substitution
Zhang, J., Cai, Y., Xiao, T., Lu, J., Peng, H., Sterling, S. M., Walsh, R. M., Rits‐Volloch, S., Zhu, H., Woosley, A. N., et al. (2021) · Science · doi:10.1126/science.abf2303 · Cited by 407
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Meng, B., Kemp, S. A., Papa, G., Datir, R. P., Ferreira, I. A. T. M., Marelli, S., Harvey, W. T., Lytras, S., Mohamed, A., Gallo, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109292 · Cited by 407
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
Oladunni, F. S., Park, J., Pino, P. A., González, O., Akhter, A., Allué‐Guardia, A., Olmo-Fontánez, A. M., Gautam, S., Garcia‐Vilanova, A., Ye, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19891-7 · Cited by 398
Touret, F., Gilles, M., Barral, K., Nougaırède, A., van Helden, J., Decroly, É., de Lamballerie, X. N., & Coutard, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-70143-6 · Cited by 397
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
Tian, F., Tong, B., Sun, L., Shi, S., Zheng, B., Wang, Z., Dong, X., & Zheng, P. (2021) · eLife · doi:10.7554/elife.69091 · Cited by 394
Covid-19 and the cardiovascular system: a comprehensive review
Azevedo, R. B., Botelho, B. G., de Hollanda, J. V. G., Ferreira, L. V. L., de Andrade, L. Z. J., Oei, S. S. M. L., Mello, T. D. S., & Muxfeldt, E. S. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0387-4 · Cited by 389
Yu, J. M., Yuan, X., Chen, H., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2020) · Blood · doi:10.1182/blood.2020008248 · Cited by 388
Self-citationNanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 387
CoV-AbDab: the coronavirus antibody database
Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383
Luan, J., Lu, Y., Jin, X., & Zhang, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.047 · Cited by 383
Self-citationStructural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 380
Xu, C., Wang, Y., Liu, C., Zhang, C., Han, W., Hong, X., Wang, Y., Qin, H., Wang, S., Zhao, Q., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe5575 · Cited by 380
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Koenig, P.-A., Das, H., Liu, H., Kümmerer, B. M., Gohr, F. N., Jenster, L., Schiffelers, L. D. J., Tesfamariam, Y. M., Uchima, M., Wuerth, J. D., et al. (2021) · Science · doi:10.1126/science.abe6230 · Cited by 380
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
Grant, O. C., Montgomery, D., Ito, K., & Woods, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-71748-7 · Cited by 379
COVID-19 and Cardiovascular Disease
Chung, M. K., Zidar, D. A., Bristow, M. R., Cameron, S. J., Chan, T. A.-T., Harding, C. V., Kwon, D. H., Singh, T. K., Tilton, J. C., Tsai, E. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.317997 · Cited by 377
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371
Mycroft‐West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Gandhi, N. S., Guimond, S. E., Miller, G. J., Meneghetti, M. C. Z., Nader, H. B., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721319 · Cited by 368
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Lv, Z., Deng, Y., Ye, Q., Cao, L., Sun, C.-Y., Fan, C., Huang, W., Sun, S., Sun, Y., Zhu, L., et al. (2020) · Science · doi:10.1126/science.abc5881 · Cited by 364
Self-citationMolecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 364
Self-citationApplications of bioluminescence in biotechnology and beyond
Syed, A. J., & Anderson, J. C. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01492c · Cited by 361
Zhou, L., Xu, Z., Castiglione, G. M., Soiberman, U., Eberhart, C. G., & Duh, E. J. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.06.007 · Cited by 352
Bienvenu, L. A., Noonan, J. E., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 349
Self-citationKreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.049 · Cited by 347
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 346
Self-citationBarton, M. I., MacGowan, S. A., Kutuzov, M. A., Dushek, O., Barton, G. J., & van der Merwe, P. A. (2021) · eLife · doi:10.7554/elife.70658 · Cited by 346
Zhou, T., Tsybovsky, Y., Gorman, J., Rapp, M., Cerutti, G., Chuang, G., Katsamba, P. S., Sampson, J. M., Schön, A., Bimela, J. S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.004 · Cited by 345
Tamura, T., Ito, J., Uriu, K., Zahradník, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38435-3 · Cited by 345
IL-6: Relevance for immunopathology of SARS-CoV-2
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.009 · Cited by 346
Liang, Y., Wang, M., Chien, C., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y., Lin, Y.-T., Chen, Y.-J., Chang, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 347
Liu, H., Ye, F., Sun, Q., Liang, H., Li, C., Li, S., Lu, R., Huang, B., Tan, W., & Lai, L. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1873977 · Cited by 343
Khan, A., Zia, T., Suleman, M., Khan, T., Ali, S. S., Abbasi, A. A., Mohammad, A., & Wei, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30367 · Cited by 341
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 335
Sex differences in severity and mortality from COVID-19: are males more vulnerable?
Pradhan, A., & Olsson, P. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00330-7 · Cited by 333
Erratum To: Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., van der Werf, S., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107405 · Cited by 330
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
Jiang, H.-W., Li, Y., Zhang, H.-N., Wang, W., Yang, X., Qi, H., Li, H., Men, D., Zhou, J., & Tao, S.-C. (2020) · Nature Communications · doi:10.1038/s41467-020-17488-8 · Cited by 329
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 327
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., Carrique, L., Malinauskas, T., Ruza, R. R., Shah, P. N. M., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.010 · Cited by 321
Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design
Xia, X. (2021) · Viruses · doi:10.3390/v13010109 · Cited by 319
Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review
Suhail, S., Zajac, J. W. P., Fossum, C. J., Lowater, H. R., McCracken, C. N., Severson, N. J., Laatsch, B. F., Narkiewicz-Jodko, A., Johnson, B., Liebau, J., et al. (2020) · The Protein Journal · doi:10.1007/s10930-020-09935-8 · Cited by 317
A potential role for integrins in host cell entry by SARS-CoV-2
Sigrist, C. J. A., Bridge, A. J., & Mercier, P. L. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104759 · Cited by 316
A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications
Changeux, J., Amoura, Z., Rey, F. A., & Miyara, M. (2020) · Comptes Rendus Biologies · doi:10.5802/crbiol.8 · Cited by 316
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 315
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2
Guo, M., Tao, W., Flavell, R. A., & Zhu, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00416-6 · Cited by 314
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 314
ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
Cuervo, N. Z., & Grandvaux, N. (2020) · eLife · doi:10.7554/elife.61390 · Cited by 313
Huston, N. C., Wan, H., Strine, M. S., Tavares, R. D. C. A., Wilen, C. B., & Pyle, A. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.041 · Cited by 311
Wang, Y., Liu, M., & Gao, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008209117 · Cited by 307
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2021) · Science · doi:10.1126/science.abf4830 · Cited by 307
Trougakos, I. P., Stamatelopoulos, K. S., Terpos, E., Tsitsilonis, O., Aivalioti, E., Paraskevis, D. N., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 305
Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
Bai, L., Zhao, Y., Dong, J., Liang, S., Guo, M. S., Liu, X., Wang, X., Huang, Z., Sun, X., Zhang, Z., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00473-1 · Cited by 305
Self-citationCOVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2
Mittal, A., Manjunath, K., Ranjan, R. K., Kaushik, S., Kumar, S., & Verma, V. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008762 · Cited by 304
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
Dhar, M. S., Marwal, R., Radhakrishnan, V. S., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., et al. (2021) · Science · doi:10.1126/science.abj9932 · Cited by 300
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 298
Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
Starr, T. N., Greaney, A. J., Hannon, W. W., Loes, A. N., Hauser, K., Dillen, J. R., Ferri, E., Farrell, A. G., Dadonaite, B., McCallum, M., et al. (2022) · Science · doi:10.1126/science.abo7896 · Cited by 298
Rapid repurposing of drugs for COVID-19
Guy, R. K., DiPaola, R. S., Romanelli, F., & Dutch, R. (2020) · Science · doi:10.1126/science.abb9332 · Cited by 297
Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
Ng, W. H., Tipih, T., Aminake, M. N., Vermeulen, J., Goedhals, D., Sempa, J. B., Burt, F. J., Taylor, A., & Mahalingam, S. (2021) · mBio · doi:10.1128/mbio.03647-20 · Cited by 296
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradník, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.018 · Cited by 293
Thomas, T. A., Stefanoni, D., Dzieciątkowska, M., Issaian, A., Nemkov, T. G., Hill, R. C., Francis, R. O., Hudson, K. E., Buehler, P. W., Zimring, J. C., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00606 · Cited by 291
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant
Zhang, J., Xiao, T., Cai, Y., Lavine, C. L., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., Mayer, M. L., et al. (2021) · Science · doi:10.1126/science.abl9463 · Cited by 288
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., et al. (2022) · Science · doi:10.1126/science.abn8863 · Cited by 284
Self-citationProgress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 284
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant
Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., & Qian, W. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.12.003 · Cited by 278
Wang, Z., Popowski, K. D., Zhu, D., Abad, B. L. D. J., Wang, X., Liu, M., Lutz, H., Naeyer, N. D., DeMarco, C. T., Denny, T. N., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00902-5 · Cited by 277
Self-citationRedox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome
Paul, B. D., Lemle, M. D., Komaroff, A. L., & Snyder, S. H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024358118 · Cited by 276
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Zhou, D., Duyvesteyn, H. M. E., Chen, C.-P., Huang, C.-G., Chen, T.-H., Shih, S.-R., Lin, Y.-C., Cheng, C.-Y., Cheng, S.-H., Huang, Y.-C., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0480-y · Cited by 274
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
Trougakos, I. P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., Kastritis, E., Andreakos, E., & Dimopoulos, M. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.007 · Cited by 273
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273
An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study
Yang, Z., Bogdan, P., & Nazarian, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81749-9 · Cited by 271
Samuel, R. M., Majd, H., Richter, M. N., Ghazizadeh, Z., Zekavat, S. M., Navickas, A., Ramirez, J. T., Asgharian, H., Simoneau, C. R., Bonser, L. R., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.11.009 · Cited by 267
Identification of Human Single-Domain Antibodies against SARS-CoV-2
Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.023 · Cited by 264
Datta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 262
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Dong, M., Zhang, J., Ma, X., Tan, J., Chen, L., Liu, S., Xin, Y., & Zhuang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110678 · Cited by 262
Cannalire, R., Cerchia, C., Beccari, A. R., Leva, F. S. D., & Summa, V. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01140 · Cited by 261
Structure of SARS-CoV-2 spike protein
Zhang, J., Xiao, T., Cai, Y., & Chen, B. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.08.010 · Cited by 261
Metadata
- Authors
- Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X.
- Affiliations
- Tsinghua University (CN)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Zhang, Qi
- Zhang, Linqi
- Wang, Xinquan
- ORCID
- Venue
- Nature
- Published
- 2020-03-30
- Volume
- 581
- Issue
- 7807
- Pages
- 215-220
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3014067025
- Cited by
- 5,983
- References
- 38
- Citations by year
- 2026: 207 · 2025: 404 · 2024: 573 · 2023: 797 · 2022: 1237 · 2021: 1678 · 2020: 1076
- FWCI
- 152.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Salt Science Research Foundation
- Tencent
- Tsinghua University (20201080053)
- Beijing Municipal Science and Technology Commission (171100000517-001 and -003)
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua University
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, spike protein, receptor binding domain, ACE2, crystal structure, SARS-CoV, convergent evolution, antibody epitopes, cross-reactive antibodies, viral entry, binding site residues
- MeSH terms
- Protein Domains, Betacoronavirus, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Amino Acid Sequence, Epitopes, Binding Sites, Humans, Hydrogen Bonding, Peptidyl-Dipeptidase A, Models, Molecular, Protein Binding, Receptors, Virus, Salts, Water, Sequence Alignment, Conserved Sequence, Crystallography, X-Ray, Evolution, Molecular, Severe acute respiratory syndrome-related coronavirus, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
